• Название:

    Психиатрия Психиатрия и психофармакотерапия им. П. Б. Ганнушкина Терапия шизофрении и шизоаффективных расстройств НЦПЗ РАМН...


  • Размер: 0.18 Мб
  • Формат: RTF
  • Сообщить о нарушении / Abuse

    Осталось ждать: 20 сек.

Установите безопасный браузер



Предпросмотр документа

: () 7

. .. - : ()

:.. ,

.. , . : (). . .. . 2005; 01:

– (), . , [1–3]. , [4, 5]. “эталонными” (, ) , [6–8], , , [9, 10] . , , PANNS. , , , , , . , , . “антиманиакальном” 421 Dunayevich . (2001 .). Alson . (2000 .) ( 400 ) I . [11] , , ( ), , , . , , [12–14], . , . -, , (-, ) . -, ( , , , , ), , - . , [15] . (24 ) (59 ) ( – . ..) .., .., .., .., ...

: 1) , , , ; 2) ( : , , ).

1 . .. ( ..) (. – . ..). 59 : - , -, -. , 1, 2, 4, 8, 12, 16, 20 24- . ( , – , – , – ) ( , ), . ( ) .. 20–50% . “отмывочного” (wash-out) , (/ – 14 , – 1 , ). : 4 25 400 600–900 , 2 . : 10 , () 30 , () 6 , () 4 , 4 , – .

:

· , -, - (- - ), - ( -10);

· ( – );

· : 1) , , ; 2) .

:

· , , , ;

· ( ) 21 60 .

, . - (34 : 12 , 22 , 35,9 ). 8,9 . : , . – 13 (5 , 8 , 33,2 ). ( ) – F25.2 ( -10). 500–800 /. 2 3 (“незначительное ” ) (, ). 10 (76,9%) . 3 “выраженное ” 6 , “улучшение” 4 (. 1).

. 1. .

. 2. ( ).

. 3. CGI - .

. 4. PANSS ( ).

. 5. HARS ( – , – HARS).

. 6. ( – , – ).

. 7. Y-BOCS ( – , – Y-BOCS).

. 8. PANSS ( , ) ( – , – PANSS).

. 9. (: – “выраженное ”, – “умеренное ”, – “минимальное ”. : D – “без ”).

. 10. PANSS - .

, * ( ) * 2 . 10 25% 2–3- , 50% – 4- (. 2). 6–8- . ( , , , ). . - (21 : 7 , 14 , 38,7 ) , - . 600–800 /. 4 15 (71,4%) (. 3). 3–4 “выраженное ” – 7 , “улучшение” – 8 . 1–2- 6–8- 30%, – 36%, – 28% – 30%. 60% PANSS 45% (. 4). : 2 6 - -. . . (6 ) , , . - . , , , , , , , (, , , ). , , , , . - (12 ; 8 , 4 ; 27,7 ). - . ( ) – ( 30–60 / – 3 , 20–40 / – 2 , 50–75 / – 1 , 37,5 – 2 ) . . 2 ( 2 4- ) . , 10 . (3 , 7 – /) (4 – , 6 – /) , . : - () – 5 , - – 5 . 1 - - () . - () / - . : 7 , 3. ( ) 8 . : (HARS), (HDRS). - , ( ) ( –) – - (Y-BOCS) – . , . . CGI “выраженное ” 6 (5 , 1 – ), “заметное ” – 3 ( ), “небольшое ” – 1 . (2 CGI) 8 . , 12- CGI 1 . ( 16- ) 20–24- . , , . HARS (. 5), 4- , 12- . . 4–8- , – 12- “литическое” (. 6). . . , Y-BOCS - . 20–24- (. 7). , . 70% , 41,5%. . , . 350–400 /, 2 – 700–800 /. . , , PANSS (. 8). , . ( ) . 20–24- . , , . ( 4- , 8- 20- ) , , - . , , . . , - . - ( , - ). - ( , ) . - , 16- , 20–24- . , . , – 4–6 6 . – , 2 .

- 13 (5 , 8 , 38,3±2,4 ) - (F20.8) . 8,4±2,1 . , . 5 (4 , 1 , 29,3±1,2 ) , – 8 (4 , 4 , 35±1,5 ) . (, ) . : – 8, – 5 . , , ( , , ) ( , , ). , ( , , ; ; ..). – , . , “ледяные” “горячие” ( W.Jareiss, 1930), , , , – ( , , ; ). (, ) 9 (72%) , 5 (39%) 4 (. 9). - ( , , ). (. 10). , , , - , , , . , , 7% . , . , ( ), . . 4 (81%) - . : 2 (30%) 8 - , [Body sensations interpretation questionnaire – BSIQ (1997). Clark DM; Salkovskis PM; Ost LG; Breitholtz E; Koehler KA; Westling BE; Jeavons A; Gelder M. In: Antony MM; Orsillo SM; Roemer L (2001). Practitioner's Guide to Empirically Based Measures of Anxiety. New York: Plenum. Pg. 106–108, 311, 360–363].. - , . , . ( ). ( - ) . , , , . . , , , . , , , , . . , , , , , , , , (-, -) .

.

1. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9: 99–107.2. Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001; 11: 207–8.3. Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001; 11: 187–91.4. Brecher M, Rak IW, Westhead EK et al. The long0term effect of quetiapine (‘Seroquel’) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–92.5. Srisuraponont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000; 2.6. Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel trial 13 Study group. Biol Psychiatry 1997; 42: 233–46.7. Copolov DL, Link CG, Kowalcyk B. A multicentre, duble-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–1I 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105.8. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68.9. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31.10. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psych Neurosci 2001; 26: 137–49.11. Zarate CA, Rothschild A, Fletcher KE et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 63,3: 185–9.12. De Nayer A, Windhager E, Irmansyan, Larmo I et al. Efficacy and tolerability of quetiapine in patients with schizophrenia-switched from other antipsychotics. Int J psych Clin Pract 2003; 7: 59–66.13. Mullen J, Jibson MD, Sweitzer D. A cjmparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Therap 2001; 23 (11): 1839–54.14. Tariot PN, Salzman C, Yeung PP et al. Clinical improvement and tolerability is Maintaned long-term in elderly patients with psychotic disorders treated with quetiapine. Am Psych Association, Ann Meeting 1999; 219: Abs NR542.15. Potenza MN, McDougle CJ. Potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs 1998; 9: 213–32.